China Pharma (CPHI) Stock: Buy, Sell, or Hold?
CPHI - China Pharma Holdings, Inc.
$0.70
-0.03 (-3.78%)
âŧ
5d:
-3.19%
30d:
+4.03%
90d:
-62.32%
WAIT
LOW Confidence
Analysis Updated: Oct 20, 2026 12:00 AM ET
Earnings: Nov 11, 2026
20d
Get Alerted When CPHI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CPHI is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CPHI is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CPHI is currently trading at $0.70, which is considered fair relative to its 30-day fair value range of $0.65 to $0.80.
Technical Outlook: Technically, CPHI is showing sideways momentum. Immediate support is located at $0.66, while resistance sits at $1.19. Short-term momentum is weak, with the stock down 3.8% recently.
Market Sentiment: CPHI scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.00 (+330.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CPHI is showing sideways momentum. Immediate support is located at $0.66, while resistance sits at $1.19. Short-term momentum is weak, with the stock down 3.8% recently.
Market Sentiment: CPHI scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.00 (+330.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.65 -
$0.80
Company Quality Score
41/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
39.5%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (25/100)
- BEARISH: Downward momentum (-3.8%)
- BULLISH: Trading 330.4% below Wall St target ($3.00)
- WARNING: Composite score 41/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.65 -
$0.80
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$0.66
Resistance Level
$1.19
Current Trend
Sideways
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
1.56
Wall Street Target
$3.00
(+330.4%)
Revenue Growth (YoY)
-7.5%
Profit Margin
-114.3%
Share & Embed Analysis
Last updated: October 21, 2026 6:14 PM ET
Data refreshes hourly during market hours. Next update: 7:14 PM
Data refreshes hourly during market hours. Next update: 7:14 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CPHI showing a specific setup today?
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
29 analysts |
$207 | 59 HOLD |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 50 HOLD |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$56 | 47 HOLD |
|
AQST
Aquestive Therapeutics IâĻ |
STRONG BUY
9 analysts |
$9 | 63 BUY |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$65 | 61 BUY |
